Previous 10 | Next 10 |
NEEDHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer will pa...
NEEDHAM, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today reported financial results for the second ...
Gary Nabel, MD, PhD, Chief Innovation Officer of OPKO Joseph Papa, Chief Executive Officer of Bausch + Lomb Corporation Renee Gaeta, Chief Financial Officer of Eko Devices NEEDHAM, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or th...
Candel Therapeutics (NASDAQ:CADL) said on Friday a mid-stage trial testing CAN-2409 in combination with anti-PD-1 or PD-L1 agents in patients with stage III/IV non-small cell lung cancer showed disease control rate of 87.5%. Additional data highlighted that most patients experienced...
Disease control rate of 87.5 percent achieved in patients who were all progressing on anti-PD-1 therapy at trial entry Durable disease stabilization that was ongoing at data cutoff in 62.5 percent of the patients who entered the study with progressive disease and were followed...
The following slide deck was published by Candel Therapeutics, Inc. in conjunction with this event. For further details see: Candel Therapeutics (CADL) Investor Presentation - Slideshow
NEEDHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will pre...
Candel Therapeutics press release (NASDAQ:CADL): Q1 GAAP EPS of -$0.03. Cash and cash equivalents as of March 31, 2022 were $94.3 million compared to $82.6 million as of December 31, 2021. For further details see: Candel Therapeutics GAAP EPS of -$0.03
NEEDHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today reported financial results for the first qu...
NEEDHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that an abstract has been accepted for presentation at the upcoming American Society...
News, Short Squeeze, Breakout and More Instantly...
Candel Therapeutics Inc. Company Name:
CADL Stock Symbol:
NASDAQ Market:
Candel Therapeutics Inc. Website:
2024-07-16 20:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 01:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEEDHAM, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL ), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Pete...